Resistance to CYP17 and AR inhibitors such as the AR-7 Splice Variant in prostate cancer

Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses resistance to CYP17 and AR inhibitors such as the AR-7 Splice Variant in prostate cancer at ASCO GU 2016 in San Francisco.